Global Ophthalmic Drugs Market Forecast up to 2024
- October, 2018
- Domain: Healthcare - Pharmaceuticals
- Get Free 10% Customization in this Report
Overview of the Ophthalmic Drugs Market
Infoholic’s market research report predicts that the global Ophthalmic Drugs market is expected to grow at a CAGR of 6.3% during the forecast period 2018–2024. Development of innovative ophthalmic drug delivery methods has aided the drug manufacturers in developing effective and advanced therapeutic tactics. The American Academy of Ophthalmology has stated that nearly 11 million individuals in the US are currently suffering from age-related macular degeneration (AMD), while almost 10% of that population have wet AMD. Such inclinations in eye ailments worldwide contribute to the development of the Ophthalmic Drugs market.
The other significant aspects that help in the improvement the market is high pervasiveness of glaucoma globally and intensification in evolution in the development of combination drugs for glaucoma. Additionally, the changing aspects in the demography worldwide are driving the growth of the market. Nevertheless, the hazard of side effects related to ophthalmic drugs and loss of patent for blockbuster drugs are hampering the market growth.
According to the ophthalmic drugs industry analysis, North America accounted for the largest share of the market in 2017. It was followed by Europe, Asia Pacific, and Rest of the World. North America alone occupied more than 35% of the ophthalmic drugs market, with a significant contribution from the US to market growth.
Ophthalmic Drugs Market Competitive Analysis and Key Vendors
In future, several blockbuster drugs that have dominated the market, are expected to lose their patents. The patents of successful products accounted for over $6 billion. The loss of patent is the most important aspect imposing a major threat to the leaders in the Ophthalmic Drugs market., Lupin Pharmaceuticals received US FDA approval in February 2015, for its bimatoprost ophthalmic solution 0.03%, the generic version of Lumigan. This affected the Allergan’s market. Formycon AG, a German biosimilars developing company is currently developing biosimilar for Eylea by Regeneron Pharmaceutical. Meanwhile, Allergan is under the threat from Akorn, which is developing a generic version of Restasis. The release of such product is likely to generate a strong burden on the market players.
Some of the key vendors in the Ophthalmic Drugs market are:
- Novartis AG
- Allergan Inc.
- Valeant Pharmaceutical International
- Santen Pharmaceutical Co. Ltd.
- Regeneron Pharmaceutical
- Johnson and Johnson
Ophthalmic Drugs Market by Indication
- Dry Eyes
- Eye Infection/Inflammation
- Retinal Disorder
In 2017, the market was dominated by Retinal Disorder segment and expected to be the fastest growing segment. However, Glaucoma was the second largest segment, owing to the high prevalence of diseases and lack of awareness among the people.
Ophthalmic Drugs Market Research Benefits
The report provides detailed information about the usage and adoption of ophthalmic drugs in various indications and regions. Additionally, key stakeholders can find out the major trends, drivers, investments, vertical player’s initiatives, government initiatives toward the product adoption in the upcoming years, along with the details of commercial products available in the market. Moreover, the report provides details about the major challenges that are going to have an impact on market growth. Furthermore, the report gives complete details about the business opportunities to key stakeholders to expand their business and capture revenues in the specific verticals. The report will help companies interested or established in this market to analyze the various aspects of this domain before investing or expanding their business in the Ophthalmic Drugs market.
1.1 Industry Overview
1.1.1 Global Drivers for Pharmaceutical Demand
1.1.2 Region-wise Pharmaceutical Spending
1.1.3 R&D Pipeline in the Pharmaceutical Industry
1.1.4 Top Pharma Drugs by Sales in 2017
1.2 Industry Trends
1.3 Total Addressable Market
2 Report Outline
2.1 Report Scope
2.2 Report Summary
2.3 Research Methodology
2.4 Report Assumptions
3 Market Snapshot
3.1 Market Definition – Infoholic Research
3.2 Segmented Addressable Market
3.2.1 Trends in the Ophthalmic Drugs Market
3.3 Related Markets
3.3.1 Bacterial Conjunctivitis Drugs
3.3.2 Contact Lenses
126.96.36.199 Trends in the contact lens market
4 Market Outline
4.1 Ophthalmic Drugs Approved by FDA
4.2 Market Segmentation
4.3 Porter 5(Five) Forces
4.4 PEST Analysis
5 Market Characteristics
5.1 Market Dynamics
188.8.131.52 Increasing prevalence of eye diseases
184.108.40.206 Increasing prevalence of cataract
220.127.116.11 Increasing aging population
18.104.22.168 Increasing mergers & acquisitions
22.214.171.124 Complex drug development process
126.96.36.199 Loss of patent for blockbuster drugs
5.2 DRO – Impact Analysis
5.3 Key Stakeholders
6 Indication: Market Size and Analysis
6.2 Dry Eyes
6.4 Eye Infection/Inflammation
6.5 Retinal Disorder
7 Regions: Market Size and Analysis
7.2 North America
7.4 Asia Pacific
7.5 Rest of the World
8 Competitive Landscape
9 Vendors Profile
9.1 Allergan PLC
9.1.2 Business Units
9.1.3 Geographic Revenue
9.1.4 Business Focus
9.1.5 SWOT Analysis
9.1.6 Business Strategies
9.2 Novartis AG
9.2.2 Business Units
9.2.3 Geographic Revenue
9.2.4 Business Focus
9.2.5 SWOT Analysis
9.2.6 Business Strategies
9.3 Pfizer Inc.
9.3.2 Business Units
9.3.3 Geographic Revenue
9.3.4 Business Focus
9.3.5 SWOT Analysis
9.3.6 Business Strategies
9.4 Valeant Pharmaceuticals International Inc. (Bausch Health)
9.4.2 Business Units
9.4.3 Geographic Revenue
9.4.4 Business Focus
9.4.5 SWOT Analysis
9.4.6 Business Strategies
9.5 Santen Pharmaceutical Co., Ltd.
9.5.2 Business Units
9.5.3 Geographic Revenue
9.5.4 Business Focus
9.5.5 SWOT Analysis
9.5.6 Business Strategies
9.6 Akorn Inc.
9.6.2 Business Focus
9.6.3 SWOT Analysis
9.6.4 Business Strategies
9.7 Johnson & Johnson
9.7.2 Business Units
9.7.3 Geographic Revenue
9.7.4 Business Focus
9.7.5 SWOT Analysis
9.7.6 Business Strategies
10 Companies to Watch for
10.1 Shire plc
10.2 Daiichi Sankyo, Inc.
10.3 Bayer AG
10.4 F. Hoffmann-La Roche (Genentech)
10.5 Sun Pharmaceuticals
Infoholic Research works on a holistic 360° approach in order to deliver high quality, validated and reliable information in our market reports. The Market estimation and forecasting involves following steps:
- Data Collation (Primary & Secondary)
- In-house Estimation (Based on proprietary data bases and Models)
- Market Triangulation
Market related information is congregated from both primary and secondary sources.
Involved participants from all global stakeholders such as Solution providers, service providers, Industry associations, thought leaders etc. across levels such as CXOs, VPs and managers. Plus, our in-house industry experts having decades of industry experience contribute their consulting and advisory services.
Include public sources such as regulatory frameworks, government IT spending, government demographic indicators, industry association statistics, and company publications along with paid sources such as Factiva, OneSource, Bloomberg among others.